Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Onivyde

- PMLiVE

Ipsen appoints new executive vp and president, primary care

Benoit Hennion will also join the executive leadership team

- PMLiVE

Servier cleared to start US trials CAR-T therapy

FDA rules studies of its Pfizer-partnered drug can be resumed

- PMLiVE

Cellectis gets FDA nod for ‘off-the-shelf’ CAR-T trial

Investigational New Drug gets go-ahead for trials in patients with two haematological cancers

- PMLiVE

Ipsen boosts specialty care and R&D leadership teams

Harout Semerjian and Dr Sotirios Stergiopoulos join

- PMLiVE

Ipsen’s chief scientific officer steps down

Dr Claude Bertrand will be replaced ad interim by Alexandre Lebeaut

- PMLiVE

Ipsen buys cancer business from stripped down Merrimack

Deal includes pancreatic cancer therapy Onivyde which it hopes will gain first-line approval

- PMLiVE

Charting a course for expansion

David Meek on Ipsen's strategic pillars and hopes in oncology

- PMLiVE

Shire wins EU licence for pancreatic cancer drug Onivyde

Combination treatment is the first approved for this patient population

- PMLiVE

Ipsen eyes first-line licence for new advanced kidney cancer drug Cabometyx

Releases phase II data from head-to-head study with Pfizer's Sutent

- PMLiVE

Amgen agrees to take Cytokinetics’ heart failure drug into phase III

Phase II results showed significant cardiac function benefit and no adverse safety signals

- PMLiVE

HIV prevention pill heads July CHMP recommendations

Gilead’s Truvada given positive opinion alongside Ipsen Pharma’s Cabometyx and Eisai’s Kisplyx

- PMLiVE

Ipsen searches for new CEO after splitting top roles

Structural reshuffle aimed at accelerating international development

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links